Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings Results

Acumen Pharmaceuticals (NASDAQ:ABOS) posted its quarterly earnings results on Tuesday. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen said ALTITUDE-AD remains on track, with top-line Phase II results expected late in 2026 and enrollment/extension transitions proceeding smoothly. Management reiterated that the study is designed to test whether sabirnetug can deliver a differentiated effect by targeting toxic Abeta oligomers rather than amyloid plaques.
• The company highlighted a potentially favorable data package from ALTITUDE-AD, including the primary endpoint (iADRS) plus secondary efficacy, safety, ARIA, and biomarker readouts. Management said a “clear win” would likely require an efficacy signal around 30% slowing or better, along with a compelling risk-benefit profile versus approved anti-amyloid drugs.
• Acumen also emphasized progress in its enhanced brain delivery (EBD) program and said it expects to exercise its option to license two JCR Pharmaceuticals compounds in Q2 2026. The company continues to target an IND filing in mid-2027 and believes the platform could improve brain penetration, distribution, and enable subcutaneous dosing.
• The balance sheet ended the quarter at $128.4 million in cash and marketable securities, which management said should fund operations into early 2027. First-quarter operating results included $16.5 million of R&D expense, $4.7 million of G&A expense, and a $20.7 million net loss.
• Management said site feedback and operational execution on ALTITUDE-AD have been strong, including a relatively fast 10-month enrollment and improved screening using plasma p-tau217 to reduce unnecessary PET scans. They also noted continued physician and KOL interest in sabirnetug and the broader anti-amyloid market despite recent skepticism about the class.

Acumen Pharmaceuticals Price Performance

Shares of ABOS traded down $0.06 during trading hours on Tuesday, reaching $2.52. 177,635 shares of the company’s stock traded hands, compared to its average volume of 694,442. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.32. The firm’s 50 day simple moving average is $2.77 and its 200-day simple moving average is $2.35. The stock has a market cap of $181.66 million, a PE ratio of -1.25 and a beta of 0.32. Acumen Pharmaceuticals has a 12 month low of $0.97 and a 12 month high of $3.60.

Analyst Upgrades and Downgrades

Several research analysts have commented on ABOS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Wednesday, April 8th. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Finally, BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of Acumen Pharmaceuticals in a research note on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Acumen Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $6.67.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in shares of Acumen Pharmaceuticals in the 1st quarter worth $46,000. Marshall Wace LLP purchased a new position in Acumen Pharmaceuticals in the second quarter worth $160,000. Qube Research & Technologies Ltd increased its stake in Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock valued at $67,000 after acquiring an additional 35,424 shares during the last quarter. Jane Street Group LLC raised its position in Acumen Pharmaceuticals by 1,526.0% during the second quarter. Jane Street Group LLC now owns 175,670 shares of the company’s stock valued at $204,000 after purchasing an additional 164,866 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its stake in Acumen Pharmaceuticals by 7.1% during the second quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company’s stock worth $957,000 after purchasing an additional 55,004 shares during the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.